Irritable Bowel Syndrome Trial, Recruiting (NCT07360938)

Irritable Bowel Syndrome Trial, Recruiting NCT07360938 Sponsor: Indiana University Condition: Irritable Bowel Syndrome

Printed from Voxsanity (voxsanity.com.au) — NCT07360938 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Irritable Bowel Syndrome

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a pro-inflammatory disease, specifically Type 2 Diabetes, Inflammatory Bowel Disease (IBD), or End-Stage Renal Disease (kidney failure)
You are able to sign a consent form agreeing to take part and allowing your health information to be used for the study

Who may not be able to join:

You have been diagnosed with, or have a history of, an autoimmune condition other than IBD — this includes conditions such as lupus, Sjögren's syndrome, multiple sclerosis, Type 1 Diabetes, Behçet's disease, or ankylosing spondylitis
You currently have an infection that requires medical treatment (however, if your infection clears up, you may be able to be re-assessed for the trial)
You are currently taking medications that suppress the immune system throughout your whole body (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 3172742744

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07360938

Sponsor: Indiana University

Phase: Not Applicable

Status: Recruiting

Condition: Irritable Bowel Syndrome

Trial contact: 3172742744

More information: https://clinicaltrials.gov/study/NCT07360938

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a pro-inflammatory disease, specifically Type 2 Diabetes, Inflammatory Bowel Disease (IBD), or End-Stage Renal Disease (kidney failure)
You are able to sign a consent form agreeing to take part and allowing your health information to be used for the study

Who may not be able to join:

You have been diagnosed with, or have a history of, an autoimmune condition other than IBD — this includes conditions such as lupus, Sjögren's syndrome, multiple sclerosis, Type 1 Diabetes, Behçet's disease, or ankylosing spondylitis
You currently have an infection that requires medical treatment (however, if your infection clears up, you may be able to be re-assessed for the trial)
You are currently taking medications that suppress the immune system throughout your whole body (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Indiana University

Registry

ClinicalTrials.gov

Start date

1 November 2025

Est. completion

31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Quantification of Plasma Cytokine Concentrations; Phenotyping of Patient Immune Cells; Quantification of the Plasma Concentrations of Endogenous Biomarkers of Drug Metabolism and Transport; Measures of Inflammatory Disease Severity; Development of Adverse Events Attributable to CYP/Transporter Substrate Medications

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov